Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Start your free trial now

Instant access. No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: NAPRELAN

« Back to Dashboard
Naprelan is a drug marketed by Almatica Pharma Inc and is included in one NDA. It is available from ten suppliers.

The generic ingredient in NAPRELAN is naproxen sodium. There are forty-two drug master file entries for this compound. Fifty-nine suppliers are listed for this compound. Additional details are available on the naproxen sodium profile page.

Summary for Tradename: NAPRELAN

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list24

Pharmacology for Tradename: NAPRELAN

Clinical Trials for: NAPRELAN

Pharmacokinetics Study Comparing Naproxen Sodium Extended Release and Naprelan
Status: Completed Condition: Pharmacokinetics

Naproxen in Preventing DNA Mismatch Repair Deficient Colorectal Cancer in Patients With Lynch Syndrome
Status: Recruiting Condition: Lynch Syndrome

A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period
Status: Completed Condition: Migraine With or Without Aura; Migraine Disorders; Migraine, Acute; Migraine Headaches

Comparison of the Clinical Efficacy of Naproxen, Associated or Not With Esomeprazol, in Lower Third Molar Removal
Status: Recruiting Condition: Pain; Other Surgical Procedures; Impacted Third Molar Tooth

A Pharmacokinetic (PK) Study Evaluating Naproxen and Esomeprazole Plasma Levels
Status: Completed Condition: Arthritis

Trial of Naproxen to Evaluate Various Methods of Measuring Analgesic Effect in Osteoarthritis Pain of the Knee
Status: Recruiting Condition: Osteoarthritis, Knee

Influence of Naproxen on Heterotropic Bone Formation Following Hip Arthroscopy
Status: Active, not recruiting Condition: Heterotopic Ossification

Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen
Status: Completed Condition: Gastric Ulcer

Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen
Status: Completed Condition: Gastric Ulcer

Naproxen for the Prevention of HO After Complex Elbow Trauma
Status: Withdrawn Condition: Heterotopic Ossification

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Almatica Pharma Inc
NAPRELAN
naproxen sodium
TABLET, EXTENDED RELEASE;ORAL020353-001Jan 5, 1996RXNo<disabled><disabled>
Almatica Pharma Inc
NAPRELAN
naproxen sodium
TABLET, EXTENDED RELEASE;ORAL020353-002Jan 5, 1996RXNo<disabled><disabled>
Almatica Pharma Inc
NAPRELAN
naproxen sodium
TABLET, EXTENDED RELEASE;ORAL020353-003Jan 5, 1996RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc